Skip to main content
SpringerLink
Log in

Gastrointestinal stromal tumours

  • Chapter
Management of Rare Adult Tumours

  • 1027 Accesses

Abstract

Gastrointestinal stromal tumours (GIST) are rare mesenchymal tumours derived from the interstitial cells of Cajal. Mutations in the KIT gene leading to a constitutively activated KIT receptor protein are the most frequent pathogenetic aberration causing clinical GIST. Diagnosis is based on a typical histomorphological appearance and the immunohistochemical detection of the KIT receptor protein (synonym CD 117).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Refrences

  1. Adenis A, Cassier PA, Bui BN et al. (2008) Does interruption of imatinib (IM) in responding patients after three years of treatment influence outcome of patients with advanced GIST included in the BFR14 trial? ASCO Meeting Abstracts 26(15 suppl): 10522

    Google Scholar 

  2. Andersson J, Bumming P, Meis-Kindblom JM et al. (2006) Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 130(6): 1573–81

    Article  CAS  PubMed  Google Scholar 

  3. Antoch G, Kanja J, Bauer S et al. (2004) Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45(3): 357–65

    CAS  PubMed  Google Scholar 

  4. Artinyan A, Kim J, Soriano P, Ellenhorn JD (2008) Survival from metastatic gastrointestinal stromal tumors in the era of imatinib. ASCO Gastrointestinal Cancers Symposium: No 50 (abstract)

    Google Scholar 

  5. Bauer S, Yu LK, Demetri GD, Fletcher JA (2006) Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 66(18): 9153–61

    Article  CAS  PubMed  Google Scholar 

  6. Benjamin RS, Choi H, Macapinlac HA et al. (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25(13): 1760–4

    Article  PubMed  Google Scholar 

  7. Blanke CD, Demetri GD, von Mehren M et al. (2008) Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26(4): 620–5

    Article  CAS  PubMed  Google Scholar 

  8. Blanke CD, Rankin C, Demetri GD et al. (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26(4): 626–32

    Article  CAS  PubMed  Google Scholar 

  9. Blay JY, Le Cesne A, Ray-Coquard I et al. (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25(9): 1107–13

    Article  CAS  PubMed  Google Scholar 

  10. Casali PG, Jost L, Reichardt P et al. (2008) Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(Suppl 2): ii35–8

    Article  PubMed  Google Scholar 

  11. Chami L, Lassau N, Koscielny S et al. (2008) Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in patients with GIST treated by thyrosine kinase inhibitor (TKI). ASCO Meeting Abstracts 26(15 suppl): 10552 (abstract)

    Google Scholar 

  12. Chetty R (2008) Small and microscopically detected gastrointestinal stromal tumours: an overview. Pathology 40(1): 9–12

    Article  PubMed  Google Scholar 

  13. Choi H, Charnsangavej C, Faria SC et al. (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13): 1753–9

    Article  PubMed  Google Scholar 

  14. Corless CL, Heinrich MC (2008) Molecular Pathobiology of Gastrointestinal Stromal Sarcomas. Annu Rev Pathol, Oct 16(epub);3(Feb):557–86

    Google Scholar 

  15. Dematteo RP, Lewis JJ, Leung D et al. (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231(1): 51–8

    Article  CAS  PubMed  Google Scholar 

  16. DeMatteo RP, Owzar K, Maki R et al. (2007) Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001, ASCO Annual Meeting (Chicago): #10079 (abstract)

    Google Scholar 

  17. Dematteo RP, Gold JS, Saran L et al. (2008) Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 112(3): 608–15

    Article  PubMed  Google Scholar 

  18. Demetri GD, van Oosterom AT, Garrett CR et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544): 1329–38

    Article  CAS  PubMed  Google Scholar 

  19. Demetri GD, Benjamin RS, Blanke CD et al. (2007) NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) — update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5(Suppl 2): S1–29; quiz S30

    Google Scholar 

  20. Demetri GD, Huang X, Garrett CR et al. (2008) Novel Statistical Analysis of Long-Term Survival to Account for Crossover in a Phase III Trial of Sunitinib versus Placebo in Advanced GIST After Imatinib Failure. J Clin Oncol 26(suppl): 35113 (abstract)

    Google Scholar 

  21. Demetri GD, Wang Y, Wehrle E et al. (2008) Correlation of imatinib plasma levels with clinical benefit in patients (pts) with unresectable/metastatic gastrointestinal stromal tumors (GIST). ASCO Gastrointestinal Cancers Symposium: No 3 (abstract)

    Google Scholar 

  22. Druker BJ, Tamura S, Buchdunger E et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2(5): 561–6

    Article  CAS  PubMed  Google Scholar 

  23. Druker B, Talpaz M, Resta DJ (1999) Clinical efficacy and safety of an Abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia. Blood 94: 368a

    Google Scholar 

  24. Fletcher CD, Berman JJ, Corless C et al. (2002) Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33(5): 459–65

    Article  PubMed  Google Scholar 

  25. George S, Blay JY, Casali PG et al. (2008) Sunitinib (SU) on a continuous daily dosing schedule in pts with advanced GIST. ASCO Gastrointestinal Cancers Symposium: No 39 (abstract)

    Google Scholar 

  26. Goerres GW, Stupp R, Barghouth G et al. (2005) The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 32(2): 153–62

    Article  CAS  PubMed  Google Scholar 

  27. Gold JS, van der Zwan SM, Gonen M et al. (2007) Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol 14(1): 134–42

    Article  PubMed  Google Scholar 

  28. Heinrich MC, Griffith DJ, Druker BJ et al. (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96(3): 925–32

    CAS  PubMed  Google Scholar 

  29. Heinrich MC, Maki RG, Corless CL et al. (2006) Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. ASCO Meeting Abstracts 24(18 suppl): 9502 (abstract)

    Google Scholar 

  30. Hirota S, Isozaki K, Moriyama Y et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350): 577–80

    Article  CAS  PubMed  Google Scholar 

  31. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344(14): 1052–6

    Article  CAS  PubMed  Google Scholar 

  32. Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353(2): 172–87

    Article  CAS  PubMed  Google Scholar 

  33. Lasota J, Miettinen M (2006) KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol 23(2): 91–102

    Article  PubMed  Google Scholar 

  34. Lassau N, Lamuraglia M, Chami L et al. (2006) Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. Am J Roentgenol 187(5): 1267–73

    Article  Google Scholar 

  35. Lugo TG, Pendergast AM, Muller A J, Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247(4946): 1079–82

    Article  CAS  PubMed  Google Scholar 

  36. Martin J, Poveda A, Llombart-Bosch A et al. (2005) Deletions Affecting Codons 557-558 of the c-KIT Gene Indicate a Poor Prognosis in Patients With Completely Resected Gastrointestinal Stromal Tumors: A Study by the Spanish Group for Sarcoma Research (GEIS). Journal of Clinical Oncology 23(25): 6190–8

    Article  CAS  PubMed  Google Scholar 

  37. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23(2): 70–83

    Article  PubMed  Google Scholar 

  38. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130(10): 1466–78

    CAS  PubMed  Google Scholar 

  39. Montemurro M, Dirnhofer S, Borner M et al. (2008) Diagnose und Behandlung von gastrointestinalen Stromatumoren (GIST) in der Schweiz — Empfehlungen einer multidisziplinären Expertengruppe. Swiss Medical Forum 8(30-31): 544–9

    Google Scholar 

  40. Montemurro M, Schöffski P, Reichardt P et al. (2008) Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST) — a Retrospective Analysis of Nilotinib in Compassionate Use. J Clin Oncol 26(suppl): 10523 (abstract)

    Google Scholar 

  41. Morgan JA, Reichardt P, Kang YK et al. (2008) Sunitinib (SU) in a worldwide treatment-use trial of patients with GIST: Safety and efficacy. ASCO Gastrointestinal Cancers Symposium: No 31 (abstract)

    Google Scholar 

  42. Nilsson B, Bumming P, Meis-Kindblom JM et al. (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era — a population-based study in western Sweden. Cancer 103(4): 821–9

    Article  PubMed  Google Scholar 

  43. Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132(3438): 1497 (abstract)

    Google Scholar 

  44. Patel SR, Zalcberg JR (2008) Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumors: Lessons from the phase 3 trials. Eur J Cancer 44: 501–9

    Article  CAS  PubMed  Google Scholar 

  45. Perol D, Domont J, Ray-Coquard IL et al. (2008) Does interruption of imatinib (IM) in responding GIST patients after one year of treatment influence the secondary resistance to IM after its reintroduction? Updated results of the prospective French Sarcoma Group randomized phase III trial on long term survival. ASCO Meeting Abstracts 26(15 suppl): 10556

    Google Scholar 

  46. Townsend DW (2008) Positron emission tomography/computed tomography. Semin Nucl Med 38(3): 152–66

    Article  PubMed  Google Scholar 

  47. Van den Abbeele A, Melenevsky Y, de Vries D et al. (2005) Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST). Proc Am Soc Clin Oncol: Abstr. 9006

    Google Scholar 

  48. Van Glabbeke M, Verweij J, Casali PG et al. (2006) Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). EurJ Cancer 42(14): 227–85

    Google Scholar 

  49. Van Glabbeke MM, Owzar K, Rankin C et al. (2007) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analysis based on 1,640 patients (pts). J Clin Oncol (Meeting Abstracts) 25(18 suppl): 10004 (abstract)

    Google Scholar 

  50. Verweij J, Casali PG, Zalcberg J et al. (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440): 1127–34

    Article  CAS  PubMed  Google Scholar 

  51. Wiebe L, Kasza KE, Maki RG et al. (2008) Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol (Meeting Abstracts) 26(15 suppl): 10502 (abstract)

    Google Scholar 

Download references

Authors
  1. M. Montemurro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J.-Y. Blay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Leyvraz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hôpital Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000, Créteil Cedex, France

    Yazid Belkacémi MD PhD (Professor Radiation Oncology, Deputy Head of the Department of Radiation Oncology) (Professor Radiation Oncology, Deputy Head of the Department of Radiation Oncology)

  2. Centre hospitalier universitaire Vaudoir, Rue du Bugnon, CH-1011, Lausanne, Switzerland

    René-Olivier Mirimanoff MD (Professeur Radiation Oncology, Head of the Department of Radiation Oncology) & Mahmut Ozsahin MD PhD (Associate Professor in the Department of Radiation Oncology) (Professeur Radiation Oncology, Head of the Department of Radiation Oncology) &  (Associate Professor in the Department of Radiation Oncology)

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Montemurro, M., Blay, JY., Leyvraz, S. (2009). Gastrointestinal stromal tumours. In: Belkacémi, Y., Mirimanoff, RO., Ozsahin, M. (eds) Management of Rare Adult Tumours. Springer, Paris. https://doi.org/10.1007/978-2-287-92246-6_16

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-92246-6_16

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-92245-9

  • Online ISBN: 978-2-287-92246-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation